Top

Cellular Oncology

Published in:

01-12-2012 | Original Paper

Drug-targeting in combined cancer chemotherapy: tumor growth inhibition in mice by association of paclitaxel and etoposide with a cholesterol-rich nanoemulsion

Authors: Iara F. Kretzer, Durvanei A. Maria, Raul C. Maranhão

Published in: Cellular Oncology | Issue 6/2012

Abstract

Background

Lipid nanoemulsions (LDE) may be used as carriers of paclitaxel (PTX) and etoposide (ETP) to decrease toxicity and increase the therapeutic action of those drugs. The current study investigates the combined chemotherapy with PTX and ETP associated with LDE.

Methods

Four groups of 10–20 B16F10 melanoma-bearing mice were treated with LDE-PTX and LDE-ETP in combination (LDE-PTX + ETP), commercial PTX and ETP in combination (PTX + ETP), single LDE-PTX, and single LDE-ETP. PTX and ETX doses were 9 μmol/kg administered in three intraperitoneal injections on three alternate days. In two control groups mice were treated with saline solution or LDE alone. Tumor growth, metastasis presence, cell-cycle distribution, blood cell counts and histological data were analyzed. Toxicity of all treatments was evaluated in mice without tumors.

Results

Tumor growth inhibition was similarly strong in all treatment groups. However, there was a greater reduction in the number of animals bearing metastases in the LDE-PTX + ETP group (30 %) in comparison to the PTX + ETP group (82 %, p < 0.05). Reduction of cellular density, blood vessels and increase of collagen fibers in tumor tissues were observed in the LDE-PTX + ETP group but not in the PTX + ETP group, and in both groups reduced melanoma-related anemia and thrombocytosis were observed. Flow cytometric analysis suggested that LDE-PTX + ETP exhibited greater selectivity to neoplastic cells than PTX-ETP, showing arrest (65 %) in the G₂/M phase of the cell cycle (p < 0.001). Toxicity manifested by weight loss and myelosuppression was markedly milder in the LDE-PTX + ETP than in the PTX + ETP group.

Conclusion

LDE-PTX + ETP combined drug-targeting therapy showed markedly superior anti-cancer properties and reduced toxicity compared to PTX + ETP.

D. Liu, N. Zhang, Cancer chemotherapy with lipid-based nanocarriers. Crit. Rev. Ther. Drug Carr. Syst. 27, 371–417 (2010)CrossRef

R.C. Maranhão, B. Garicochea, E.L. Silva, P. Dorlhiac-Llacer, F.J.C. Pileggi, D.A.F. Chamone, Increased plasma removal of microemulsions resembling the lipid phase of low-density lipoproteins (LDL) in patients with acute myeloid leukemia: a possible new strategy for the treatment of the disease. Braz. J. Med. Biol. Res. 25, 1003–1007 (1992)PubMed

R.C. Maranhão, T.B. Cesar, M.T.B. Pedroso, M.H. Hirata, C.H. Mesquita, Metabolic behavior in rats of a non protein microemulsion resembling LDL. Lipids 28, 691–696 (1993)PubMedCrossRef

R.C. Maranhão, B. Garicochea, E.L. Silva, P. Dorlhiac-Llacer, S.M.S. Cadena, I.J.C. Coelho, J.C. Meneguetti, F.J.C. Pileggi, D.A.F. Chamone, Plasma kinetics and biodistribution of a lipid emulsion resembling low density lipoprotein in patients with acute leukemia. Cancer Res. 54, 4660–4666 (1994)PubMed

R.D. Hirata, M.H. Hirata, C.H. Mesquita, T.B. Cesar, R.C. Maranhão, Effects of apolipoprotein B-100 on the metabolism of a lipid microemulsion model in rats. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1437, 53–62 (1999)CrossRef

Y.K. Ho, R.G. Smith, M.S. Brown, J.L. Goldstein, Low-density lipoprotein (LDL) receptor activity in human acute myelogenous cells. Blood 52, 1099–1114 (1978)PubMed

H. Ginsberg, H.S. Gilbert, J.C. Gibson, N.A. Le, W.V. Brown, Increased low-density-lipoprotein catabolism in myeloproliferative disorders. Ann. Intern. Med. 96, 311–316 (1982)PubMed

P. Henriksson, S. Ericsson, R. Stege, M. Ericsson, M. Rudling, L. Berglund, B. Angelin, Hypocholesterolaemia and increased elimination of low-density lipoproteins in metastatic cancer of the prostate. Lancet 2, 1178–1180 (1989)PubMedCrossRef

S. Vitols, B. Angelin, S. Ericsson, G. Gahrton, G. Juliusson, M. Masquelier, C. Paul, C. Peterson, M. Rudling, K. Soderberg-Reid, V. Tidefelt, Uptake of low-density lipoproteins by human leukemic cells in vivo: relation to plasma lipoprotein levels and possible relevance for selective chemotherapy. Proc. Nati. Acad. Sci. USA 87, 2598–2602 (1990)CrossRef

10.

Y. Ueyama, Y. Matsuzawa, S. Yamashita, T. Funahashi, N. Sakai, T. Nakamura, M. Kubo, S. Taru, Hypocholesterolaemic factor from gallbladder cancer cells. Lancet 336, 707–709 (1990)PubMedCrossRef

11.

S. Vitols, C. Peterson, O. Larsson, P. Holm, B. Aberg, Elevated uptake of low density lipoproteins by human lung cancer tissue in vivo. Cancer Res. 52, 6244–6247 (1992)PubMed

12.

T. Nakagawa, Y. Ueyama, S. Nozaki, S. Yamashita, M. Menju, T. Funahashi, K. Kameda-Takemura, M. Kubo, K. Tokunaga, T. Tanaka, Marked hypocholesterolemia in a case with adrenal adenoma-enhanced catabolism of low density lipoprotein (LDL) via the LDL receptors of tumor cells. J. Clin. Endocrinol. Metab. 80, 92–96 (1995)PubMedCrossRef

13.

A. Stranzl, H. Schmidt, R. Winkler, G.M. Kostner, Low-density lipoprotein receptor mRNA in human breast cancer cells: influence by PKC modulators. Breast Cancer Res. Treat. 42, 195–205 (1997)PubMedCrossRef

14.

Y. Chen, M. Hughes-Fulford, Human prostate cancer cells lack feedback regulation of low-density lipoprotein receptor and its regulator, SREBP2. Int. J. Cancer 91, 41–45 (2001)PubMedCrossRef

15.

R.C. Maranhão, S.R. Graziani, N. Yamaguchi, R.F. Melo, M.C. Latrilha, D.G. Rodrigues, R.D. Couto, R. Schreiber, A.C. Buzaid, Association of carmustine with a lipid emulsion: in vitro, in vivo and preliminary studies in cancer patients. Cancer Chemother. Pharmacol. 49, 487–498 (2002). doi:10.1007/s00280-002-0437-3 PubMedCrossRef

16.

V.T. Hungria, M.C. Latrilha, D.G. Rodrigues, S.P. Bydlowski, C.S. Chiattone, R.C. Maranhão, Metabolism of a cholesterol-rich microemulsion (LDE) in patients with multiple myeloma and a preliminary clinical study of LDE as a drug vehicle for the treatment of the disease. Cancer Chemother. Pharmacol. 53, 51–60 (2004). doi:10.1007/s00280-003-0692-y PubMed

17.

K.V. Pinheiro, V.T. Hungria, E.S. Ficker, C.J. Valduga, C.H. Mesquita, R.C. Maranhão, Plasma kinetics of a cholesterol-rich microemulsion (LDE) in patients with Hodgkin’s and non-Hodgkin’s lymphoma and a preliminary study on the toxicity of etoposide associated with LDE. Cancer Chemother. Pharmacol. 57, 624–630 (2005). doi:10.1007/s00280-005-0090-8 PubMedCrossRef

18.

C.J. Antalis, A. Uchida, K.K. Buhman, R.A. Siddiqui, Migration of MDA-MB-231 breast cancer cells depends on the availability of exogenous lipids and cholesterol esterification. Clin. Exp. Metastasis 28, 733–741 (2011). doi:10.1007/s10585-011-9405-9 PubMedCrossRef

19.

L.A. Pires, R. Hegg, E.R. Freitas, E.R. Tavares, C.P. Almeida, E.C. Baracat, R.C. Maranhão, Effect of neoadjuvant chemotherapy on low-density lipoprotein (LDL) receptor and LDL receptor-related protein 1 (LRP-1) receptor in locally advanced breast cancer. Braz. J. Med. Biol. Res. 45, 557–564 (2012). doi:10.1590/S0100-879X2012007500068 PubMedCrossRef

20.

C.H. Azevedo, J.P. Carvalho, C.J. Valduga, R.C. Maranhão, Plasma kinetics and uptake by the tumor of a cholesterol-rich microemulsion (LDE) associated to etoposide oleate in patients with ovarian carcinoma. Gynecol. Oncol. 97, 178–182 (2005). doi:10.1016/j.ygyno.2004.12.015 PubMedCrossRef

21.

M.L. Dias, J.P. Carvalho, D.G. Rodrigues, S.R. Graziani, R.C. Maranhão, Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers. Cancer Chemother. Pharmacol. 59, 105–111 (2007). doi:10.1007/s00280-006-0252-3 PubMedCrossRef

22.

L.A. Pires, R. Hegg, C.J. Valduga, S.R. Graziani, D.G. Rodrigues, R.C. Maranhão, Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study. Cancer Chemother. Pharmacol. 63, 281–287 (2009). doi:10.1007/s00280-008-0738-2 PubMedCrossRef

23.

R.S. Teixeira, R. Curi, R.C. Maranhão, Effects on Walker 256 tumor of carmustine associated with a cholesterol-rich microemulsion (LDE). J. Pharm. Pharmacol. 56, 909–914 (2004). doi:10.1211/0022357023826 PubMedCrossRef

24.

C.J. Valduga, D.C. Fernandes, A.C. Lo Prete, C.H.M Azevedo, D.G. Rodrigues, R.C. Maranhão, Use of a cholesterol-rich microemulsion that binds to low-density lipoprotein receptors as vehicle for etoposide. J. Pharm. Pharmacol. 55, 1615–1622 (2004). doi:10.1211/0022357022232 CrossRef

25.

A.C. Lo Prete, D.A. Maria, D.G. Rodrigues, C.J. Valduga, O.C. Ibanez, R.C. Maranhão, Evaluation in melanoma-bearing mice of an etoposide derivative associated to a cholesterol-rich nano-emulsion. J. Pharm. Pharmacol. 58, 801–808 (2006). doi:10.1211/jpp.58.6.0010 PubMedCrossRef

26.

D.G. Rodrigues, D.A. Maria, D.C. Fernandes, C.J. Valduga, R.D. Couto, O.C. Ibanez, R.C. Maranhão, Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies. Cancer Chemother. Pharmacol. 55, 565–576 (2005). doi:10.1007/s00280-004-0930-y PubMedCrossRef

27.

R.S. Teixeira, C.J. Valduga, L.A. Benvenutti, S. Schreier, R.C. Maranhão, Delivery of daunorubicin to cancer cells with decreased toxicity by association with a lipidic nanoemulsion that binds to LDL receptors. J. Pharm. Pharmacol. 60, 1287–1295 (2008). doi:10.1211/jpp/60.10.0004 PubMedCrossRef

28.

K.R. Hande, Topoisomerase II inhibitors. Update on Cancer Therapeutics 1, 3–15 (2006). doi:10.1016/j.uct.2006.04.001 CrossRef

29.

Q. Yue, X. Liu, D. Guo, Microtubule-Binding Natural Products for Cancer Therapy. Planta Med. 76, 1037–1043 (2010). doi:10.1055/s-0030-1250073 PubMedCrossRef

30.

R.I. Geran, N.H. Greenberg, M.M. Macdonald, A.M. Schumacher, B.J. Abbott, Protocols for screening chemical agents and natural products against animal tumors and other biological systems, 3rd edn. (National Institute of Health, Bethesda, 1972), pp. 47–51

31.

A.J. Versluis, P.J. van Gell, H. Oppelaar, T.J.C. van Berkel, M.K. Bijsterbosch, Receptor-mediated uptake of low-density lipoprotein by B16 melanoma cells in vitro and in vivo in mice. Br. J. Cancer 74, 525–532 (1996)PubMedCrossRef

32.

A. Ades, J.P. Carvalho, S.R. Graziani, R.F. Amancio, J.S. Souen, J.A. Pinotti, R.C. Maranhão, Uptake of a cholesterol-rich emulsion by neoplasic ovarian tissues. Gynecol. Oncol. 82, 84–87 (2001). doi:10.1006/gyno.2001.6203 PubMedCrossRef

33.

L.C. van Kempen, J. Rijntjes, I. Mamor-Cornelissen, S. Vincent-Naulleau, M.J. Gerritsen, D.J. Ruiter, M.C. van Dijk, C. Geffrotin, G.N. van Muijen, Type I collagen expression contributes to angiogenesis and the development of deeply invasive cutaneous melanoma. Int. J. Cancer 122, 1019–1029 (2008). doi:10.1002/ijc.23147 PubMedCrossRef

34.

K.P. Claffey, L.F. Brown, L.F. del Aguila, K. Tognazzi, K.T. Yeo, E.J. Manseau, H.F. Dvorak, Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res. 56, 172–181 (1996)PubMed

35.

R. Ophir, G. Moalem, M. Pecht, M. Shashoua, G. Rashid, S. Ben-Efraim, N. Trainin, Y. Burstein, Y. Keisari, THF-gamma 2-mediated reduction of pulmonary metastases and augmentation of immunocompetence in C57BL/6 mice bearing B16-melanoma. J. Immunother. 22, 103–113 (1999)PubMedCrossRef

36.

E.A. Perez, Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol. Cancer Ther. 8, 2086–2095 (2009). doi:10.1158/1535-7163.MCT-09-0366 PubMedCrossRef

37.

I. Schonn, J. Hennesen, D.C. Dartsch, Cellular responses to etoposide: cell death despite cell cycle arrest and repair of DNA damage. Apoptosis 15, 162–172 (2010). doi:10.1007/s10495-009-0440-9 PubMedCrossRef

38.

F. Wei, Y. Xie, L. Tao, D. Tang, Both ERK1 and ERK2 kinases promote G2/M arrest in etoposide-treated MCF7 cells by facilitating ATM activation. Cell. Signal. 22, 1783–1789 (2010). doi:10.1016/j.cellsig.2010.07.007 PubMedCrossRef

39.

H.L. Lin, Y.F. Chang, T.Y. Liu, C.W. Wu, C.W. Chi, Submicromolar paclitaxel induces apoptosis in human gastric cancer cells at early G1 phase. Anticancer. Res. 18, 3443–3449 (1998)PubMed

40.

K. Torres, S.B. Horwitz, Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res. 58, 3620–3626 (1998)PubMed

41.

P. Giannakakou, R. Robey, T. Fojo, M.V. Blagosklonny, Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene 20, 3806–3813 (2001)PubMedCrossRef

42.

P.C. Liao, C.H. Lieu, Cell cycle specific induction of apoptosis and necrosis by paclitaxel in the leukemic U937 cells. Life Sci. 76, 1623–1639 (2005). doi:10.1016/j.lfs.2004.09.021 PubMedCrossRef

43.

Z.N. Demidenko, S. Kalurupalle, C. Hanko, C.U. Lim, E. Broude, M.V. Blagosklonny, Mechanism of G1-like arrest by low concentrations of paclitaxel: next cell cycle p53-dependent arrest with sub G1 DNA content mediated by prolonged mitosis. Oncogene 27, 4402–4410 (2008)PubMedCrossRef

44.

B.B. Lundberg, V. Risovic, M. Ramaswamy, K.M. Wasan, A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration. J. Control. Release 86, 93–100 (2003)PubMedCrossRef

Title: Drug-targeting in combined cancer chemotherapy: tumor growth inhibition in mice by association of paclitaxel and etoposide with a cholesterol-rich nanoemulsion
Authors: Iara F. Kretzer
Durvanei A. Maria
Raul C. Maranhão
Publication date: 01-12-2012
Publisher: Springer Netherlands
Published in: Cellular Oncology / Issue 6/2012
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI: https://doi.org/10.1007/s13402-012-0104-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2012

Aberrant promoter methylation of the RASSF1A and APC genes in epithelial ovarian carcinoma development

CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort

HIF-1α and NOTCH signaling in ductal and lobular carcinomas of the breast

Interpretation of interlocking key issues of cancer stem cells in malignant solid tumors

High expression of heme oxygenase-1 is associated with tumor invasiveness and poor clinical outcome in non-small cell lung cancer patients

EGFR status and KRAS/BRAF mutations in intestinal-type sinonasal adenocarcinomas

Keynote webinar | Spotlight on antibody–drug conjugates in cancer